Dr. Poul Sorensen, investigator, Michael Cuccione Childhood Cancer Research Program at BC Children's Hospital; professor in the faculty of medicine at the University of British Columbia
Dr. Poul Sorensen, an investigator with the Michael Cuccione Childhood Cancer Research Program at BC Children's and a professor in the faculty of medicine at the University of British Columbia, is the principal investigator of the UBC component of the St. Baldrick’s Foundation-Stand Up To Cancer (SUTC) Pediatric Cancer Dream Team. The group helps develop new immunotherapy approaches for high-risk childhood cancers.
The Dream Team is being recognized for significant contributions to the pediatric cancer research community including the genesis of more than 319 published manuscripts, submission of 44 patent applications, creation of a new clinical trials network, generation of more than $118 million to support innovative research, and for contributing to the treatment of over 1,113 children on early phase clinical trials, with many demonstrating durable complete responses.
Dr. Sorensen, also a distinguished scientist at the BC Cancer Research Centre and the Asa and Kashmir Johal Endowed Chair in Childhood Cancer Research, says he is extremely grateful for this award.
“I am deeply honored and indeed humbled to be a part of this powerful and effective team,” Dr. Sorensen said. “The Dream Team epitomizes the power of team science, as everyone on the team has a role to play, and is equally important for bringing new therapies to pediatric cancer patients.
"This group also captures the essence of translational medical research, in which diverse people from across different scientific, clinical, and other disciplines come together to share their expertise, in order to expediently deliver exciting new innovations to the clinic."
The Dream Team now consists of about 200 researchers across 10 leading children’s hospitals and childhood cancer-focused research programs. The St. Baldrick’s Foundation and SU2C launched the Pediatric Cancer Dream Team with a grant of $14.5 million over a four-year term beginning in 2013. In that time, the team worked to improve and expand immunotherapy in childhood cancers. In particular, the team integrated insights from the field of genomics into immunotherapy to identify new therapeutic targets and develop new drugs. In 2017, the St. Baldrick’s Foundation renewed its commitment with an additional $8 million in funding. Furthermore, the eight institutions that were part of the consortium at that time, pledged to match the St. Baldrick’s Foundation grant to bring the total of additional funding to $16 million, including the BC Cancer Foundation for the Vancouver funding component.
“From establishing novel immunotherapies for pediatric cancer, to giving hope to thousands of children and their families through the clinical trial network it established, the St. Baldrick’s Foundation-SU2C Pediatric Cancer Dream Team has made incredible advancements in pediatric cancer research,” said Margaret Foti, chief executive officer of the AACR.
“The AACR is proud to honor these two remarkable leaders of the program and all those involved in this project since 2013 with this prestigious AACR team science award.”
The AACR Team Science Award was established in 2007 to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and the translation of research discoveries into clinical cancer applications. The award recognizes an outstanding interdisciplinary team of researchers for their innovative and meritorious science that has advanced or may advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advancing the detection, diagnosis, prevention, or treatment of cancer.
The Vancouver team also includes:
Dr. Kirk Schultz, director of the Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital; co-lead of the Childhood Cancer & Blood Research Group, BC Children's; professor in the faculty of medicine at UBCKirk R. Schultz, director of the Michael Cuccione Childhood Cancer Research Program and co-lead of the Childhood Cancer & Blood Research Group at BC Children's Hospital, and a professor in the faculty of medicine at UBC
Alberto Delaidelli, PhD student with the Sorensen Research Team at BC Children’s and in the Sorensen Lab at BC Cancer Research,
Mads Daugaard, associate professor, department of urologic sciences; senior research scientist, Vancouver Prostate Centre, head, Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre
Anne-Chloe Dhez, postdoctoral research fellow, BC Cancer Research, Sorensen Lab
Htoo Z. Oo, Molecular Pathologist, Daugaard Lab
Patrick J. Sullivan, parent advocate
Anne Steino, program manager, BC Cancer Research, Sorensen and Daugaard Labs
Melanie Rouleau, program manager, BC Cancer Research, Sorensen Lab
Haifeng Zhang, postdoctoral fellow, department of pathology and laboratory medicine, BC Cancer Research, Sorensen Lab
Globally, pneumonia and malaria are among the leading causes of death for children under five, due in part to health-care resource gaps in low- and middle-income countries. New BCCHR investigator and pediatric infectious diseases expert Dr. Michael T. Hawkes is developing diagnostic and treatment tools to address these shortages.
Dr. Kirk Schultz, an investigator at BC Children’s Hospital Research Institute, has been awarded the 2024 Geoffrey L. Hammond Lectureship in recognition of his leadership and significant contributions to improving the health and well-being of children in British Columbia and around the world.
To help prevent more children from dying of sepsis, the Institute for Global Health is inviting researchers to help design an open-source algorithm that predicts in-hospital mortality in low- and middle-income countries.
Researchers at BC Children's Hospital Research Institute are working with human-induced pluripotent stem cells to develop safer and more effective treatments for kids with hypertrophic cardiomyopathy.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.
